This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Nis Register Study Comparing Seroquel and Seroquel Prolong

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: August 24, 2009
Last updated: February 15, 2011
Last verified: February 2011
The general aim of this non interventional study is to clarify what are the current clinical treatment practices of Quetiapine Immediate Release and Quetiapine Extended Release. The primary objectives of the study are:1.To collect information on the used Quetiapine Immediate Release or Quetiapine Extended Release medication 2.To collect information on duration and number of hospitalisation days 3.Change of GAF points

Comparing Hospitalisation Time With Seroquel and Seroquel Prolong

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective
Official Title: A Local Non Interventional Retrospective Register Study of the Current Clinical Treatment Practices and the Number of Hospitalization Days With Seroquel or Seroquel Prolong.

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Hospitalisation time [ Time Frame: 2008-2010 ]
  • Treatment practice [ Time Frame: 2008-2010 ]

Secondary Outcome Measures:
  • Primary diagnosis [ Time Frame: 2008-2010 ]
  • Medication at the end of hospitalisation [ Time Frame: 2008-2010 ]
  • GAF rating points [ Time Frame: 2008-2010 ]

Estimated Enrollment: 200
Study Start Date: August 2009
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Seroquel Prolong


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
South Karelia Central Hospital in-patients

Inclusion Criteria:

  • Medication: Seroquel or Seroquel Prolong
  • Diagnosis: F20-F29 or F30-F31 (ICD-10)
  • In-patient

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00965536

Research Site
Lappeenranta, Finland
Sponsors and Collaborators
Study Director: Yrjö Ovaskainen Medical Affairs Manager, MD, psychiatrist
Principal Investigator: Kari Hänninen MD, psychiatrist
  More Information

Responsible Party: MC MD, AstraZeneca Identifier: NCT00965536     History of Changes
Other Study ID Numbers: NIS-NFI-SER-2009/1
Study First Received: August 24, 2009
Last Updated: February 15, 2011

Keywords provided by AstraZeneca:
Bipolar Disorder
Manic Disorder
Register study
Quetiapine Prolong
Seroquel Prolong
Seroquel XR

Additional relevant MeSH terms:
Quetiapine Fumarate
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs processed this record on August 18, 2017